Scientists have developed a new drug RPL554 that could treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease COPD in two ways at once, according to new research published in The Lancet Respiratory Medicine. RPL554 has the potential to both reverse the narrowing of the airways bronchodilation and reduce inflammation quicker and with fewer side effects than current therapies.
“Further longer term studies of RPL554 are now eagerly awaited because this could be one of the most substantial advances for some time in the management of patients with chronic airway obstruction”, writes Professor Jadwiga A Wedzicha from University College London, UK, in a linked Comment.
The unique inhaled dual inhibitor — two actions in a single molecule — works by impeding the ability of two enzymes from the phosphodiesterase family PDE3 and PDE4 to inhibit processes that help relax airway smooth muscle and reduce inflammation.
more New class of drug shows promise for treating asthma and COPD | YottaFire.